Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?

AbbVie leans on immunology and a cheaper valuation, while Eli Lilly’s obesity and diabetes drugs are driving faster growth and higher margins.

Summary by The Motley Fool
AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.

1 Articles

The Motley FoolThe Motley Fool
Lean Left

AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?

AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.

·Alexandria, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Left
100% Left

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

The Motley Fool broke the news in Alexandria, United States on Thursday, September 24, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

AbbVie icon

AbbVie

Eli Lilly icon

Eli Lilly

Novo Nordisk icon

Novo Nordisk

United States icon

United States

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal